| Allergic rhinitis (disorder)
Qnasl vs Dymista
Side-by-side clinical, coverage, and cost comparison for allergic rhinitis (disorder).Deep comparison between: Qnasl vs Dymista with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsDymista has a higher rate of injection site reactions vs Qnasl based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Dymista but not Qnasl, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Qnasl
Dymista
At A Glance
Intranasal
Daily
Intranasal corticosteroid
Nasal spray
Twice daily
H1 antagonist/corticosteroid combination
Indications
- Allergic rhinitis (disorder)
- Allergic rhinitis (disorder)
Dosing
Allergic rhinitis (disorder) - Adults and Adolescents (>=12 years) 320 mcg per day as 2 actuations in each nostril once daily (maximum 4 actuations per day) via QNASL 80 mcg Nasal Aerosol.
Allergic rhinitis (disorder) - Children (4 to 11 years) 80 mcg per day as 1 actuation in each nostril once daily (maximum 2 actuations per day) via QNASL 40 mcg Nasal Aerosol.
Allergic rhinitis (disorder) 1 spray (137 mcg azelastine hydrochloride and 50 mcg fluticasone propionate) per nostril twice daily, by nasal route only.
Contraindications
- History of hypersensitivity to beclomethasone dipropionate and/or any other QNASL Nasal Aerosol ingredients
- Hypersensitivity to azelastine hydrochloride, fluticasone propionate, or any other ingredient of DYMISTA (including anaphylaxis)
Adverse Reactions
Most common (>=1%), adults and adolescents (>=12 years) Nasal discomfort, epistaxis, headache
Most common (>=2%), pediatric (4 to 11 years) Headache, pyrexia, upper respiratory tract infection, nasopharyngitis
Serious Epistaxis, nasal ulcerations, Candida albicans infection, impaired wound healing, eye disorders, hypercorticism, adrenal suppression, growth reduction, immunosuppression
Postmarketing Sneezing, burning sensation, nasal septal perforation, blurred vision, glaucoma, cataracts, central serous chorioretinopathy, loss of taste and smell, anaphylaxis, angioedema, rash, urticaria, bronchospasm
Most common (>=2%) Dysgeusia, headache, epistaxis
Serious Somnolence, epistaxis, nasal ulceration, nasal septal perforation, impaired wound healing, Candida albicans infection, glaucoma, cataracts, immunosuppression, hypercorticism, adrenal suppression
Postmarketing Atrial fibrillation, palpitations, increased heart rate, blurred vision, cataracts, glaucoma, increased intraocular pressure, nausea, vomiting, anaphylaxis, growth suppression, disturbance or loss of smell and/or taste, dizziness, urinary retention, bronchospasm, dyspnea, nasal septal perforation, angioedema, hypertension
Pharmacology
Beclomethasone dipropionate is a prodrug corticosteroid converted to the active metabolite beclomethasone-17-monopropionate, which inhibits inflammatory cells (mast cells, eosinophils, basophils, lymphocytes, macrophages, neutrophils) and release of inflammatory mediators (histamine, eicosanoids, leukotrienes, cytokines) involved in allergic rhinitis.
DYMISTA combines azelastine hydrochloride, a histamine H1-receptor antagonist (phthalazinone derivative), and fluticasone propionate, a synthetic trifluorinated corticosteroid that exerts anti-inflammatory activity on multiple cell types (mast cells, eosinophils, macrophages, lymphocytes) and mediators (histamine, leukotrienes, cytokines) involved in allergic rhinitis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Qnasl
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (9/12) · Qty limit (9/12)
Dymista
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Qnasl
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (0/8)
Dymista
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Qnasl
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (2/3) · Qty limit (3/3)
Dymista
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Qnasl.
No savings programs available for Dymista.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
DymistaView full Dymista profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.